In part 2 of this 2-part interview, Jason Bock, founder and CEO of CTMC provides input on how the FDA’s proposed manufacturing registration rule may impact personalized therapies.
Listen to Part 2 here: PharmTech Part 2
In part 2 of this 2-part interview, Jason Bock, founder and CEO of CTMC provides input on how the FDA’s proposed manufacturing registration rule may impact personalized therapies.
Listen to Part 2 here: PharmTech Part 2